Qiming Venture Partners’ Post

FDA Grants Approval to Augtyro™ (Repotrectinib) for ROS1-Positive Lung Cancer Bristol Myers Squibb has received FDA approval for Augtyro, a next-generation Tyrosine Kinase Inhibitor (TKI), as a treatment for ROS1-positive non-small cell lung cancer. Augtyro demonstrated high response rates and durable responses in clinical trials. The drug targets ROS1 oncogenic fusions and offers hope for patients with this rare form of lung cancer. The FDA approval is based on the successful results of the TRIDENT-1 trial. Augtyro comes with certain warnings and precautions, and is expected to be available to patients in the US in mid-December 2023. This approval is significant for precision medicine in lung cancer and provides hope for patients with ROS1-positive NSCLC. For more details please click the link! https://lnkd.in/gXdm6xdh #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

NX-1607, a First-in-Class Inhibitor of Casitas B-Lineage Lymphoma-b (CBL-B) for Immuno-Oncology with Frederick Cohen from Nurix Therapeutics. The E3 ubiquitin ligase CBL-B is expressed in multiple immune cell lineages and is a master regulator of immune response. NX-1607 is a molecule that glues CBL-B into an inactive conformation lowering the threshold for T cell activation. In cancer models, NX-1607 inhibits tumor growth when dosed orally. We present preclinical data on NX-1607, supporting its advancement to clinical testing, and pharmacokinetic-pharmacodynamic (PK-PD) data from the FIH trial (NCT05107674). https://lnkd.in/e8NAGvXe Save $150 with Discount code SPK150. #drugdiscoverychemistry

Breakthrough in Pancreatic Cancer: FDA Endorses Ipsen’s Onivyde as First-Line Treatment Onivyde, a treatment for pancreatic cancer, has been approved by the FDA for first-line treatment, potentially changing the way metastatic pancreatic adenocarcinoma is managed. The drug, also known as pegylated liposomal irinotecan, is now approved for use in combination with the NALIRIFOX regimen. This marks the first new treatment option for previously untreated patients in over a decade. The approval is based on the results of the NAPOLI-3 study, which showed improved overall survival and progression-free survival compared to the standard treatment regimen. Ipsen, the company behind Onivyde, sees this approval as an opportunity to reach a wider patient population and a significant advancement in managing the disease. For more details please click the link! https://lnkd.in/dmvSjqf7 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Exciting news for the oncology community as MSD's Keytruda has received expanded FDA approval for use in combination with chemotherapy for the treatment of advanced cervical cancer! 🎉 This decision comes after promising results from the phase 3 KEYNOTE-826 trial, which demonstrated a significant improvement in progression-free survival for patients receiving the combination treatment. This approval represents a significant advancement in the fight against cervical cancer and provides hope for patients who are facing this challenging diagnosis. It also underscores the importance of ongoing research and development efforts in the field of oncology ✅🔍📈 It's humbling to see the ongoing commitment to the fight against cancer and continued efforts on the journey towards improving cancer treatments - Amazing work! 💊👏🏼 #Oncology #CervicalCancer #KeytrudaApproval #Biotechnology #Pharmaceuticals #ClinicalResearch #ClinicalTrials #LifeScience #ElxirAssociates #StaffingPartner

Today on World Lung Cancer Day, we want to raise awareness of the most aggressive form of lung cancer: Small Cell Lung Cancer (#SCLC). At DISCO Pharmaceuticals GmbH, using our target discovery platform, we have completed the first-ever mapping of the SCLC #surfaceome. This has revealed countless novel proteins and protein communities on the surface of SCLC cells providing target🎯candidates for mono- and bi-specific #antibodytherapeutics Using this knowledge, we have launched the development of SCLC target-specific therapeutics to improve #patient care by providing more effective, targeted treatment options. To learn more about our cell surfaceome discovery technology, visit the link in the comments below. #WorldLungCancerDay #WLCD2024 #LungCancerAwareness #SmallCellLungCancer

A Milestone in Treating Ovarian Cancer: FDA Grants Full Approval to Elahere The FDA has granted full approval to Elahere, an antibody-drug conjugate (ADC), for the treatment of FRα-positive, platinum-resistant ovarian cancer. Elahere is the first and only ADC approved for this indication in the United States. The approval is seen as a significant breakthrough in the field of oncology and offers new hope for patients with this challenging malignancy. The SORAYA trial demonstrated Elahere's anti-tumor activity and tolerability, with 31.7% of patients achieving a confirmed objective response rate. The MIRASOL trial further supported Elahere's efficacy, showing superiority in overall survival and progression-free survival compared to chemotherapy. This approval marks a milestone in the treatment landscape for ovarian cancer and highlights the importance of targeted therapies in addressing unmet medical needs. For more details please click the link! https://lnkd.in/dm_-PYut #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

RLY-2608: An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models | https://lnkd.in/gxRdfabf RLY-2608 is an oral, mutant-selective PI3Kα allosteric inhibitor discovered by Relay Therapeutics that targets a cryptic pocket near the ATP-binding site. Given the challenges and toxicities associated with WT PI3Kα inhibition like hyperglycemia and rash, there's a growing need for next-generation mutant-selective PI3Kα allosteric inhibitors. Currently undergoing Ph. I clinical trials, RLY-2608 holds promise as a single agent and in combination with fulvestrant for HR+/HER2- breast cancer treatment. Explore the notable discovery strategy, mutant selectivity profile and novel mechanism of selectivity, how it compares to other molecules, preclinical activity, recent clinical developments, and more in this review article. Full Article: https://lnkd.in/gxRdfabf

#Melanoma_Cancer_Diagnostics Market Share Expected Huge Growth during 2022-2030 https://lnkd.in/dE8CtT8X The market for #melanoma cancer diagnostics is predicted to grow as the prevalence of melanoma skin #cancer rises. Increased exposure to ultraviolet radiation in factories, the sun, and other places eventually leads to increased melanoma skin cancer instances, propelling the melanoma cancer #diagnostic market forward. Inhalation Sciences Sweden AB Incyte Merck Group Novartis Pierre Fabre Group Amgen Amgen Deutschland AstraZeneca Bristol Myers Squibb Bristol Myers Squibb UK & Ireland Daiichi Sankyo, Inc.

Breaking News! 🎉 OBI Pharma's OBI-992 has received Orphan Drug Designation from the US FDA for treating gastric cancer, including gastroesophageal junction cancer. This designation encourages innovation for rare diseases, and we're thrilled to advance OBI-992 in our clinical trials. #OBIPharma #OrphanDrug #CancerResearch #Oncology #Biotech #Innovation https://lnkd.in/gmJyucen

Antibody-drug conjugates (ADCs) represent a class of targeted cancer therapeutics designed to deliver cytotoxic drugs specifically to cancer cells while minimizing systemic toxicity. ADCs combine the specificity of monoclonal antibodies (mAbs) with the potent cell-killing ability of cytotoxic drugs, thereby enhancing the therapeutic index. https://lnkd.in/gfxJ8Qj6 #ADCs #AntibodyDrugConjugates #CancerTherapeutics #TargetedTherapy #MonoclonalAntibodies #CytotoxicDrugs #TherapeuticIndex #AntibodyDiscovery #KMDBioscience